Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anbarasan Sekar
Observed names:
A. Sekar,
Sekar Anbarasan
Institutions:
Homi Bhabha National Institute,
Tata Memorial Hospital,
Advanced Centre for Treatment, Research and Education in Cancer
Observed institutions:
Homi Bhabha National Institute,
Tata Memorial Hospital,
Madras Medical Mission,
Advanced Centre for Treatment, Research and Education in Cancer
ORCID:
0000-0001-7665-261X
Observed ORCID:
0000-0001-7665-261X
OpenAlex ID:
A5059467220
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial
2024
·
Jyoti Bajpai
, Venkatesh Kapu
, et al.
·
The Lancet Oncology
·
50
Caregiver burden in older Indian patients with cancer- Experience from a tertiary care center
2022
·
Nandini Menon
, Vijay M. Patil
, et al.
·
Journal of Geriatric Oncology
·
42
Phase 3 RCT comparing docetaxel-platinum with docetaxel-platinum-5FU as neoadjuvant chemotherapy in borderline resectable oral cancer
2024
·
Vanita Noronha
, Vijay Patil
, et al.
·
European Journal of Cancer
·
23
Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort
2022
·
Jyoti Bajpai
, Lakhan Kashyap
, et al.
·
The Breast
·
19
Epidemiological Trend of Esophageal Cancer at a Tertiary Cancer Center in Mumbai, India, Over the Past 15 Years
2022
·
Vanita Noronha
, Anbarasan Sekar
, et al.
·
Journal of Gastrointestinal Cancer
·
9
PDF
Demographics, Pattern of Care & Outcomes of Primary CNS Lymphoma- Experience from a Tertiary Care Cancer Center in India
2022
·
Shasanka Das
, Bhausaheb Bagal
, et al.
·
Indian Journal of Hematology and Blood Transfusion
·
6
The epidemiological trend of esophageal cancer in Mumbai, India over the past two decades.
2021
·
Anbarasan Sekar
, Akhil Rajendra
, et al.
·
Journal of Clinical Oncology
·
5
Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors
2021
·
Amit Kumar Choudhary
, George Abraham
, et al.
·
Indian Journal of Surgical Oncology
·
4
Retrospective Study to Determine Factors Influencing Outcome in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Receiving Neoadjuvant Chemotherapy
2025
·
Minit Shah
, Sushmita Rath
, et al.
·
JCO Global Oncology
·
2
PDF
Predictive significance of inflammatory markers in the survival of older Indian patients with cancer: a single-center prospective analysis
2024
·
Abhijith Rajaram Rao
, Vanita Noronha
, et al.
·
ecancermedicalscience
·
2
Adjuvant therapy may improve overall survival in high-risk periampullary adenocarcinomas patients – A match-pair analysis from a multi-institutional cohort study (The MIPPAP study)
2024
·
Anant Ramaswamy
, Vikram Chaudhari
, et al.
·
HPB
·
2
PDF
Combination chemotherapy and hormone therapy in patients with hormone receptor positive and HER2 negative metastatic breast cancer
2025
·
Kripa Bajaj
, Sushmita Rath
, et al.
·
Scientific Reports
·
1
PDF
Acupuncture as a modality of treatment for chemotherapy-induced peripheral neuropathy in breast cancer: A phase 3 randomized controlled trial (ABC-CIPN).
2024
·
Jyoti Bajpai
, Venkatesh Kapu
, et al.
·
Journal of Clinical Oncology
·
1
An unusual site of ablation for a ventricular tachycardia
2023
·
Anindya Ghosh
, Anbarasan Sekar
, et al.
·
Journal of Arrhythmia
·
1
Practice Patterns and Survival in Patients with Resected Pancreatic Ductal Adenocarcinomas (PDAC) — Results from the Multicentre Indian Pancreatic & Periampullary Adenocarcinoma Project (MIPPAP) Study
2023
·
Vikram Chaudhari
, Anant Ramaswamy
, et al.
·
Journal of Gastrointestinal Cancer
·
1
An Audit of Systemic Therapy in Medullary Carcinoma Thyroid
2021
·
Aditya Pavan Kumar Kanteti
, George Abraham
, et al.
·
Indian Journal of Surgical Oncology
·
1
Approach to geriatric oncology patients during the coronavirus disease 2019 pandemic: A changing treatment paradigm
2020
·
Anbarasan Sekar
·
Cancer Research Statistics and Treatment
·
1
Evaluation of Circulating Tumor Cells Expressing PD-L1 and CTC Clusters at Baseline and Follow ups in Triple-negative Breast Cancer
2026
·
Khandare Jayant
, Rakesh Ramesh
, et al.
·
The Journal of Liquid Biopsy
PDF
Correction: Patient derived xenograft models of hormone receptor positive and HER2 negative breast cancer from Indian patients
2026
·
Khusbhoo A. Gandhi
, Rohan Chaubal
, et al.
·
Scientific Reports
PDF
Real-world experience in the management of primary mediastinal germ cell tumour-resource-limited settings (PMGCT-RWE)
2026
·
Anbarasan Sekar
, Saurabh Bagra
, et al.
·
South Asian Journal of Cancer
PDF
Self-Reported Compliance With Adjuvant Endocrine Therapy in Young Women With Hormone Receptor-Positive Early Breast Cancer: A Real-World Study from a Tertiary Cancer Center in India
2026
·
Mehak Trikha
, Sushmita Rath
, et al.
·
Clinical Breast Cancer
A retrospective analysis of BCOR-immunohistochemistry positive uterine sarcomas: Clinical features and survival
2026
·
Anbarasan Sekar
, Bharat Rekhi
, et al.
·
Journal of Cancer Research and Therapeutics
Real-world effectiveness and safety of adjuvant capecitabine in triple-negative breast cancer (TNBC) patients with residual disease following neoadjuvant chemotherapy.
2026
·
Anbarasan Sekar
, Sanjana Malokar
, et al.
·
Journal of Clinical Oncology
Early clinical outcomes, treatment adherence, and toxicity profile of adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: Real-world data from India
2026
·
Anuradha Mehta
, Debdeep Samaddar
, et al.
·
Indian Journal of Cancer
391P An evaluation of the Khorana Score (KS) and risk factors predicting thromboembolism (TE) in pancreatic ductal adenocarcinomas (PDAC): A cohort study
2025
·
P. Vana
, T. Chawla
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
33
Citation count:
170
H-index:
6
I10-index:
4
Year
Topic
Type